Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | MELK | Q14680 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL593367 | 0.95 | OPRM1 (0.34) | OPRM1OPRL1OPRK1PTGS2GRIN2D | |
| SCHEMBL13031022 | 0.89 | BACE1 (0.39) | DRD2SIGMAR1ALDH1A1 | |
| SCHEMBL8267608 | 0.86 | OPRM1 (0.36) | OPRM1OPRL1OPRK1CHRM4KMO | |
| SCHEMBL593222 | 0.84 | JAK2 (0.34) | — | |
| SCHEMBL10149121 | 0.80 | OPRL1 (0.42) | OPRM1OPRL1OPRK1GRIN2DGRIN3B | |
| Trifluoroacetic Acid SCHEMBL3479657 | 0.80 | GPR6 (0.34) | — | |
| SCHEMBL592322 | 0.75 | PRKAA2 (0.35) | — | |
| SCHEMBL13031014 | 0.75 | BACE1 (0.36) | — | |
| SCHEMBL594333 | 0.75 | FAAH (0.35) | PTGS2 | |
| SCHEMBL594222 | 0.75 | MLNR (0.35) | OPRM1OPRK1DRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114887-B2 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-02-14 | — | — | US | claimed |
| EP-1804794-B1 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER S DISEASE | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-1804794-B1 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER S DISEASE | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8114887-B2 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114887-B2 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114887-B2 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| WO-2006044497-A2 | SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER’S DISEASE | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | BACE1, BACE2, APP | OPRM1 4346/4885OPRL1 1765/4885OPRK1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.